Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Silo Pharma, Inc. - Common Stock (NQ:SILO)

0.4159 -0.0041 (-0.98%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Silo Pharma, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
News headline image
Psyched: 5-MeO-DMT For Depression, Utah Hospitals Providing Therapy, Elon Musk And Meta's Influence ↗
 
Via Benzinga
News headline image
Psyched: LSD, Psilocybin As Breakthrough Therapies, $14M Fed Grant For Ibogaine, Indiana's Research And More ↗
 
Via Benzinga
Topics Economy
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Exercises Option for Exclusive License Agreement for SPC-15
Via Investor Brand Network
News headline image
Silo Pharma Exercises Option for Exclusive License Agreement for First-in-Class PTSD and Stress-Induced Anxiety Therapeutic
From Silo Pharma, Inc.
Via GlobeNewswire
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Files Patent Application for Groundbreaking Ketamine Implant Therapeutic
Via Investor Brand Network
Topics Intellectual Property
News headline image
Silo Pharma Files Patent for Groundbreaking Ketamine Implant Therapeutic to Target Fibromyalgia and Chronic Pain
From Silo Pharma, Inc.
Via GlobeNewswire
News headline image
Psyched: New Evidence Shows Psilocybin As Anxiety Therapy, Open-Source Learning For Therapists, Enveric's Licensing Deals And More ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
 
Via Benzinga
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Completes Successful Dose-Ranging Study in Advancement of SPC-15
Via Investor Brand Network
News headline image
Silo Pharma Completes Successful Dose-Ranging Study of SPC-15 Intranasal Therapeutic for PTSD
From Silo Pharma, Inc.
Via GlobeNewswire
News headline image
Psyched: Psychedelics & Sex, MDMA And Federal Approval, Canadians For End-Of-Life Care And More ↗
 
Via Benzinga
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Announces Validation of Delivery System for SP-26
Via Investor Brand Network
News headline image
Silo Pharma’s SP-26 Ketamine Implant Demonstrates Successful Drug Delivery
From Silo Pharma, Inc.
Via GlobeNewswire
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) to Prioritize Clinical Pipeline Targeting Mental Health, Chronic Pain and Neurology
Via Investor Brand Network
News headline image
Silo Pharma Announces Pipeline Prioritization for 2024 Targeting Mental Health, Chronic Pain, and Neurology
From Silo Pharma, Inc.
Via GlobeNewswire
News headline image
Psyched: Suggestibility And Psychedelics' Effects, EU's $7M Research Fund, Australia's Treatment Delivery, BZ Podcast And More ↗
New study finds suggestibility plays a role in antidepressant effects of psilocybin therapy. EU invests 6.5M euros in psychedelics for pulmonary disorder, MS, ALS, and Parkinson's. Australian... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
 
Via Benzinga
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Highlights Positive Results of Alzheimer’s Study
Via Investor Brand Network
News headline image
Silo Pharma Announces Positive Results in Alzheimer’s Disease Study
From Silo Pharma, Inc.
Via GlobeNewswire
News headline image
Psyched: $100M For MDMA Therapy, VA Funds, 2024 Watchlist, Reform Updates And More ↗
Psychedelics Developer Secures $100M In Series A Funding, Will Support MDMA Approval To Treat PTSD 
Via Benzinga
News headline image
Psyched: Ibogaine For TBI, Kentucky Initiative Stalled, DEA Quotas, Insurance Codes, Atai's $50M And More ↗
Ibogaine Therapy Shows Promising Outcomes For Veterans With Trauma Brain Injury 
Via Benzinga
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Successfully Completes First Phase of Dose-Ranging SPC-15 Study
Via Investor Brand Network
News headline image
Silo Pharma Concludes First Phase of Dose-Ranging Study Of Intranasal Treatment For Post Traumatic Stress Disorder ↗
Thursday, Silo Pharma Inc (NASDAQ: SILO) provided an update on its previously announced dose-ranging study of SPC-15, a targeted prophylactic treatment for post-traumatic stress disorder (PTSD).  
Via Benzinga
News headline image
Silo Pharma Successfully Completes First Phase of Dose-Ranging Study of SPC-15 an Intranasal Treatment for PTSD
From Silo Pharma, Inc.
Via GlobeNewswire
News headline image
Fibromyalgia Care Breakthrough: DEA Green Lights Biotech Partnership Exploring Ketamine Implant Therapy ↗
Silo Pharma’s (NASDAQ: SILO) novel ketamine-loaded implant targeting fibromyalgia and chronic pain conditions, SP-26, is reportedly ad 
Via Benzinga
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Announces Regulatory Approval for Ketamine Implant, Moves Forward with Partner to Next Stage of Development
Via Investor Brand Network
News headline image
Silo Pharma and Partner Receive Regulatory Approval to Begin Development of Ketamine Implant for Fibromyalgia
From Silo Pharma, Inc.
Via GlobeNewswire
News headline image
Psyched: Biden Approves Psychedelics Trials, RFK, Australia's First Legal Dedicated Clinic & More ↗
President Biden Approves Psychedelics Clinical Trials For Active Military Members President Biden signed into law the 2024 National Defense Authorization Act (NDAA), large-scale legislation that also... 
Via Benzinga
News headline image
Psyched: Biden's Big Decision On Psychedelics Therapy; LSD Anxiety Results; Matthew Perry Autopsy And More ↗
Biden To Decide On Psychedelic Therapy Bill 
Via Benzinga
News headline image
Psyched: John Lennon Remembered, Clinical Trials For Service Members, Chrissy Teigen, Jon Feliciano And More ↗
John Lennon Remembered 43 Years After His Murder In New York, Psychedelic Adventures & Enduring Legacy 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.